Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
2.67M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
439K
-
Shares change
-
+275K
-
Total reported value, excl. options
-
$2.21M
-
Value change
-
+$1.38M
-
Number of buys
-
10
-
Number of sells
-
-3
-
Price
-
$5.03
Significant Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q3 2025
17 filings reported holding LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share as of Q3 2025.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 439K shares
of 2.67M outstanding shares and own 16.45% of the company stock.
Largest 10 shareholders include HighTower Advisors, LLC (99.4K shares), RENAISSANCE TECHNOLOGIES LLC (73.2K shares), Federation des caisses Desjardins du Quebec (50.9K shares), VANGUARD GROUP INC (48.5K shares), DRW Securities, LLC (48.5K shares), GEODE CAPITAL MANAGEMENT, LLC (41.4K shares), Ethos Financial Group, LLC (24.8K shares), STATE STREET CORP (17.4K shares), UBS Group AG (16.7K shares), and Atlas Legacy Advisors, LLC (13.8K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.